Item no. |
S1172-100 |
Manufacturer |
Selleckchem
|
CASRN |
881202-45-5 |
Amount |
100 mg |
Category |
|
Type |
Inhibitors |
Specific against |
other |
ECLASS 5.1 |
30220300 |
ECLASS 6.1 |
30220300 |
ECLASS 8.0 |
32160605 |
ECLASS 9.0 |
32160605 |
ECLASS 10.0.1 |
32160490 |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
881202-45-5' |
Similar products |
JNJ |
Available |
|
Administration |
Administered via p.o. |
Animal Models |
CB17SC scid-/- female mice. |
Cell lines |
OCI-AML-3, MOLM-13, NB4 and U937 cells |
Chemical Name |
N1-(2-(1H-indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1, 4-diamine |
Clinical Trials |
JNJ 26854165 is currently being evaluated in Phase I clinical trials in patients with Neoplasms. |
Concentrations |
0-10 uM |
Description |
JNJ 26854165 (Serdemetan) is an orally bioavailable HDM2 antagonist. |
Dosages |
<=20 mg/kg |
Formulation |
JNJ-26854165 is dissolved in DMSO and then diluted in water. |
In vitro |
JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 uM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates, proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis, of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3] |
In vivo |
JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4] |
Incubation Time |
72 hours |
Method |
Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK |
Molecular Weight (MW) |
328, 41 |
Picture ChemicalStructure Description |
JNJ 26854165 (Serdemetan) Chemical Structure |
Solubility (25C) |
DMSO 66 mg/mL, Water <1 mg/mL, Ethanol 2 mg/mL |
Storage |
2 years -20CPowder, 2 weeks4Cin DMSO, 2 months-80Cin DMSO |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.